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chromatographyAbstract A simple, rapid, selective and reproducible reversed-phase high performance liquid chro-
matographic (RP-HPLC) method has been developed and validated for the estimation of release of
Candesartan cilexetil (CC) in tablets. Analysis was performed on an Agilent, Zorbax C8 column
(150 mm · 4.6 mm, 5 lm) with the mobile phase consisting of phosphate buffer (pH 2.5)–acetoni-
trile (15:85, v/v) at a ﬂow rate of 1.0 mL/min. UV detection was performed at 215 nm and the reten-
tion time for CC was 2.2. The calibration curve was linear (correlation coefﬁcient = 1.000) in the
selected range of analyte. The optimized dissolution conditions include the USP apparatus 2 at a
paddle rotation rate of 50 rpm and 900 mL of phosphate buffer (pH 7.2) with 0.03% of polysorbate
80 as dissolution medium, at 37.0 ± 0.5 C. The method was validated for precision, linearity, spec-
iﬁcity, accuracy, limit of quantitation and ruggedness. The system suitability parameters, such as
theoretical plate, tailing factor and relative standard deviation (RSD) between six standard
replicates were well within the limits. The stability result shows that the drug is stable in the
Figure 1 Chemical structure o
S868 V. Kamalakkannan et al.prescribed dissolution medium. Three different batches (A, B and C) of the formulation containing
8 mg of Candesartan cilexetil was performed with the developed method and the results showed no
signiﬁcant differences among the batches.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Candesartan cilexetil (CC) is a commercially available
antihypertensive prodrug containing one chiral center at the
cyclohexyloxycarbonyloxy ethyl ester group (Ross and
Papademetriou, 2004) (Fig. 1). In the gastrointestinal (GI) tract
CC is rapidly absorbed and completely bioactivated by ester
hydrolysis at the ester link, converted to active candesartan
(McClellan and Goa, 1998). An important clinical application
of CC is an angiotensin receptor blocker with insurmountable
binding properties to the angiotensin-1 receptor, long duration
of action and improved efﬁcacy (Joost et al., 2011). Further-
more, it is a white to off-white crystalline powder with a molec-
ular mass of 61 kDa. The solubility nature in benzyl alcohol is
0.3 M, and is insoluble in water (<8 · 10–8 M). The partition
coefﬁcient (Coctanol/Caqueous) at pH 1.1, 6.9 and 8.9 is >1000
indicating high hydrophobicity character (ATACAND). It
has a pKa value of 6.0 (Cagigal et al., 2001).
Analytical method validation is a process to conﬁrm that
the analytical procedure employed for a speciﬁc test is suitable
for its intended use. Food and Drugs Administration (FDA)
regulations such as Good Manufacturing Practice (GMP),
Good Laboratories Practice (GLP), Good Clinical Practice
(GCP) and quality standards such as International Organiza-
tion for Standardization (ISO17025) require analytical
methods to be validated before and during routine use (Physi-
cians’ Desk Reference, 2009). Method validation is deﬁned as
the process of proving through scientiﬁc studies that an analyt-
ical method is acceptable for its intended use. USP provides
regulatory guidance for method validation (FDA, 2000) and
recent guidelines for methods development and validation
for new non-compendial test methods are provided by the
FDA draft document (USP 25-NF 20, 2002).
Developing dissolution methods for poorly soluble com-
pounds has been a consistent challenge for the pharmaceutical
scientist. Because of inherently slow dissolution, poorly soluble
compounds are good candidates for developing in vitro and
in vivo correlations (IVIVCs) if intestinal permeability is high
and drug dissolution is the controlling mechanism for the re-
lease of drug from the dosage form (ICH, 2000). Drug absorp-
tion from a dosage form after oral administration depends onf Candesartan cilexetil.the release of the drug from the pharmaceutical formulation,
the dissolution and/or its solubilization under physiological
conditions and the permeability across the gastrointestinal
tract. Because of the critical nature of the ﬁrst two of these
steps in vitro dissolution may be relevant to the prediction of
in vivo performance (Amidon et al., 1995; Emami, 2006).
Over the past decade several published literatures reported
that there is no validated method for dissolution and moreover
no ofﬁcial monograph was available for CC. Parameters to set
up the dissolution test should be researched and deﬁned for the
drugs that do not possess ofﬁcial monographs (Emami, 2006).
Importantly, the present work describes the development and
validation of an accurate and reliable RP-HPLC method for
the estimation of CC release in solid dosage form. The best dis-
solution conditions were used to evaluate the development and
validation of a dissolution method and this method was used
to evaluate the dissolution proﬁle of three different batches
of tablets.2. Experimental
2.1. Chemicals and reagents
The pure drug CC was obtained as a free gift sample from
Caplin point laboratories limited, Puducherry, India. Acetoni-
trile was purchased from Merck (India) Ltd. Sodium dihydro-
gen orthophosphate, phosphoric acid, potassium dihydrogen
orthophosphate, polysorbate 80 and sodium hydroxide were
procured from SD ﬁne chemicals, Bangalore, India. All other
reagents used were of analytical grade.
2.2. Instruments
USP type 2 rotating paddle apparatus (Electrolab, TDT-08L)
was used to study the drug dissolution proﬁle. The dissolution
mediumwasdeaeratedbyvacuumﬁltration and the temperature
maintained at 37.0 ± 0.5 C throughout the study.Drug release
estimation was performed using RP-HPLC equipped with agi-
lent 1200 series quaternary pump (DE62974693) with a variable
wavelength detector (DE71367145) at 215 nm and the pH of all
solutions were determined byHanna pHanalyzer (microproces-
sor pH 211).3. Method
3.1. Determination of solubility and dissolution optimization
Candesartan cilexetil solubility was determined using 900 mL
of puriﬁed water, 0.1 N hydrochloric acid, acetate buffer
(pH 1.2–2.2) and phosphate buffer (pH 4.5–7.2) with an
amount of drug equivalent to three times of the dose in the
pharmaceutical formulation (US Pharmacopoeia, 2007). Drug
release was carried out as per USP dissolution general
Figure 2 The cumulative release curves of Candesartan cilexetil
from tablets at different medium.
Figure 3 In vitro release proﬁle (n= 6) of three batches of
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drawn at pre-determined time intervals (15, 30, 45 and 60 min),
and replaced with an equal volume of dissolution medium to
maintain a constant total volume of 900 mL. To assess the sta-
bility of CC in dissolution medium, samples were diluted by
phosphate buffer (pH 7.2) with 0.03% polysorbate 80. The
prepared solutions kept at different conditions, such as room
temperature and at 37.0 ± 0.5 C for 24 and 2 h, respectively.
The stability of these solutions was studied by comparing the
values obtained with freshly prepared sample solutions.
3.2. Analytical method validation
RP-HPLC method was used to analyze the CC samples in
phosphate buffer (pH 7.2). Validation was carried out for pre-
cision, linearity, speciﬁcity, accuracy, limit of quantitation and
ruggedness according to US Pharmacopoeia (FDA, 1997) and
International Conference on Harmonization (ICH) guideline
(ICH (Q2R1), 2007). An isocratic HPLC analysis was per-
formed on Agilent, Zorbax C8 (150 · 4.6 mm, 5 lm) column
maintained at ambient condition. Chromatographic separa-
tion was achieved with the mobile phase ratio of 15:85 (v/v)
mixture of phosphate buffer (pH 2.5) and acetonitrile at a ﬂow
rate of 1.0 mL/min. Injection volume was 20 lL and the liquid
chromatograph was equipped with variable wavelength detec-
tor at 215 nm.
3.3. Evaluation of system suitability
Twentymicroliters of standard solutionwas injected in triplicate
before and after the analysis and the chromatograms were re-
corded. System suitability parameters like theoretical plate, tail-
ing factor were also recorded. RSD of six replicates of standard
was also taken.The columnefﬁciency as determined from the ac-
tive peak is not less than6000USP theoretical plates.USP tailing
factor for the same peak is notmore than 2.0 andRSDof six rep-
licates of the standard solution is not more than 2.0%.Candesartan cilexetil tablet.4. Results and discussion
4.1. Optimization of dissolution test conditions
The accomplishment of dissolution proﬁle is recommended as
a support in the development and optimization of drug formu-
lation as well as in the establishment of in vitro/in vivo correla-
tion. When dissolution test is not deﬁned or if the monograph
is not available, comparison of drug dissolution proﬁles is rec-
ommended on three different dissolution mediums (pH 1–7.5).
In vitro dissolution was used to perform the release rate of drug
products and to assure the quality of solid dosage forms by the
pharmaceutical industry and regulatory agencies (ICH
(Q2R1), 2007). The sink conditions are determined and ex-
pressed as a percentage of drug released. Puriﬁed water,
0.1 N hydrochloric acid, acetate buffer (pH 1.2–2.2) and phos-
phate buffer (pH 4.5–7.2) were used as dissolution medium
and selected on the basis of solubility and screening study.
From the above study the phosphate buffer (pH 7.2) provided
highest drug release proﬁle with greater stability, ensured
excellent sink conditions and was selected as the best dissolu-
tion medium. The drug release proﬁles are shown in Fig. 2.
Based on the solubility and screening study, phosphate buffer(pH 7.2), was selected as the dissolution medium and USP type
2 rotating paddle apparatus at 50 rpm as an instrument. In
these conditions, typical acceptance criteria for the amount
of drug dissolved were in the range of 65–83%. In the present
study, the percentage of drug released for all three different
products were >80% in 60 min (Fig. 3) and the suggested
acceptance criteria can be 75 (Q) in 60 min. The stability test
indicated that CC is stable in the dissolution medium at room
temperature and at 37.0 ± 0.5 C for 24 and 2 h, respectively.
The results obtained from the initial and ﬁnal response factors
were within the acceptable range and not much difference
between the stability and freshly prepared solutions.
4.2. Analytical method validation
In the current study, RP-HPLC method was used to determine
the percentage drug release. HPLC is used to separate, identify
and determine the concentration of a speciﬁc component in a
mixture, moreover that this method is very fast, reproducible
and easy to operate (Pharmacopoeial Forum, 2004). The
developed method was validated to meet the requirements
for a global regulatory ﬁling. The validation parameters such
Figure 4 Linearity graph of candesartan cilexetil.
Table 1 Linear regression of Candesartan cilexetil.
Concentration (mcg/mL) Areaa (average) Standard deviation RSD
2 4,360,646.3 26,083 0.598
4 8,762,327.3 3492.8 0.04
8 17,528,692.7 7573.4 0.043
12 26,288,297.3 5351.3 0.02
16 35,063,016.3 19,091.7 0.054
20 43,809,040.7 4709.3 0.011
a Average of ﬁve determinations.
Table 2 Calculation of regression line.
X (concentration in lg/mL) Y (area obtained in mAU)a XY X2 Y2
2 4,360,646.3 8,721,292.6 4 1.90152E+13
4 8,762,327.3 35,049,309.2 16 7.67784E+13
8 17,528,692.7 140,229,541.6 64 3.07255E+14
12 26,288,297.3 315,459,567.6 144 6.91075E+14
16 35,063,016.3 561,008,260.8 256 1.22942E+15
20 43,809,040.7 876,180,814.0 400 1.91923E+15
a Average of ﬁve determinations.
Table 3 Slope calculation.
X axis Y axisa Y intercept Slope
2 4,360,646.3 9862 2,185,254.2
4 8,762,327.3 9862 2,193,047.3
8 17,528,692.7 9862 2,192,319.3
12 26,288,297.3 9862 2,191,513.3
16 35,063,016.3 9862 2,192,054.9
20 43,809,040.7 9862 2,190,945.1
a Average of ﬁve determinations.
S870 V. Kamalakkannan et al.as precision, linearity, speciﬁcity, accuracy, limit of quantita-
tion and ruggedness were carried out in accordance with
ICH and US Pharmacopoeia guidelines.
4.2.1. Linearity
The linearity of CC response is evaluated from the range of
2.0–20.0 mcg/mL and showed a good correlation coefﬁcient
(r2) = 1.0. To validate linearity, the standard curve of CC
was constructed by plotting concentration (mcg/mL) versus
area response (mAU) which is shown in Fig. 4. The
linear regression and slope were calculated and are shown in
Tables 1–3.
4.2.2. Speciﬁcity
Speciﬁcity is carried out with placebo solution and compared
with the standard preparation. The drug release of CC in the
dissolution medium was measured at 215 nm and the run time
was extended up to 30 min. Two peaks were observed in the
chromatogram, the major and minor peaks retention time
was 2.2 and 1.3, respectively. The primary peak was due to
polysorbate 80 and was conﬁrmed by correlating with the blankpeak. The main peak was well separated from the blank peak
and the resolution between these two peaks was more than 2
(Fig. 5). There were no other additional peaks observed which
indicate no interferences by excipients and thus demonstrating
that the proposed method is speciﬁc for the analysis of CC.
4.2.3. Precision
The precision of an analytical procedure expresses the close-
ness of the agreement (degree of scatter) between a series of
Figure 5 Standard chromatogram of Candesartan cilexetil.
Table 4 Precision, intermediate and intraday precision of Candesartan cilexetil.
Replicates Chemist-I (area)a Chemist-II (area)a Column-I (area)a Column-II (area)a
Area-1 13,773,622 13,765,439 13,773,622 13,975,643
Area-2 13,991,726 13,756,393 13,991,726 13,759,234
Area-3 13,874,337 13,756,394 13,874,337 13,759,320
Area-4 13,705,374 13,850,324 13,705,374 13,856,290
Area-5 13,553,809 13,786,439 13,553,809 13,822,233
Area-6 13,571,089 13,745,633 13,571,089 13,944,752
Average 13,744,993 13,776,770 13,744,993 13,852,912
Standard deviation 171,341.9 38,554 171,341.9 91,635
RSD 1.247 0.2798 1.247 0.6615
a Average of ﬁve determinations.
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homogeneous sample under the prescribed conditions. Repeat-
ability is a measure of the precision under the same operating
conditions over a short interval of time and it is also known as
intra assay precision. A minimum six determinations at 100%
of the standard concentration were tested to ﬁnd out the aver-
age, standard deviation and related standard deviation, and all
the calculated parameters were well within the prescribed limit.
Intra-day precision and intermediate precision were done for
ensuring the robustness of the method. The related standard
deviation (RSD) of both the tests was well within the desirable
limit of NMT 1.8% which is clearly indicated that the devel-
oped method is robust. Intraday and intermediate precision re-
sults are shown in Table 4.
4.2.4. Accuracy
The accuracy of an analytical procedure is the closeness of
agreement between the values that are accepted either as con-
ventional true values or an accepted reference value. Accuracy
is usually reported as percent recovery by an assay using the
proposed analytical procedure of known amount of analyte
added to the sample. The ICH also recommended assessing aminimum of three determinations over a minimum of three
concentration levels covering the speciﬁed range. The common
method of determining accuracy is to apply the analytical pro-
cedure to the drug substance and to be quantitated against the
reference standard of known purity. The range for the accu-
racy limit should be within the linear range. Typical accuracy
of the recovery of the drug substance in the mixture is expected
to be about 98–102%. Values of accuracy of the recovery data
beyond this range are to be investigated. The precision concen-
tration was 10 mcg/mL, hence the linearity range was selected
from 7 to 14 mcg/mL. The known concentration of (20%,
40%, 60%, 80% and 100%) were added to the standard prep-
aration (7 mcg/mL). The percentage recoveries obtained were
considered under the acceptable range as per the ICH guide-
lines (Table 5).
4.2.5. Limit of quantitation
Limit of quantitation (LOQ) is the lowest amount of analyte in
a sample that can be determined with acceptable precision and
accuracy under stated experimental conditions. The quantita-
tion limit is expressed as the concentration of analyte in the
sample. The standard deviation and related standard deviation
Table 5 Accuracy of Candesartan cilexetil.
Solution Quantity added (known %) Areaa Average area Standard deviation RSD Recovery Actual value Accuracy
Soln-1 100 (7 mcg/mL) 9,629,430 9,654,878 43,944.8 0.455 – – –
9,629,583
9,705,621
Soln-2 120 (8.4 mcg/mL) 11,583,211 11,572,808 12,646.94 0.109 119.86 120 99.89
11,558,731
11,576,483
Soln-3 140 (9.8 mcg/mL) 13,588,943 13,744,906 150,576.3 1.096 142.36 140 101.69
13,756,329
13,889,445
Soln-4 160 (11.2 mcg/mL) 15,234,754 15,425,980 182,200.9 1.181 159.77 160 99.86
15,597,564
15,445,623
Soln-5 180 (12.6 mcg/mL) 17,123,893 17,347,168 234,157.7 1.350 179.67 180 99.82
17,326,740
17,590,870
Soln-6 200 (14 mcg/mL) 19,345,786 19,540,023 317,808.7 1.626 202.39 200 101.19
19,367,501
19,906,783
a Average of three determinations.
S872 V. Kamalakkannan et al.for the limit of quantitation were 15,686.2 and 1.1067%,
respectively, which was well within the desirable limit of not
more than 2.0%. The lowest quantiﬁable concentration was
1 mcg/mL and this parameter can be used for predicting the
drug release in low dose formulation.
4.2.6. Ruggedness
Intraday and intermediate precision were determined by ana-
lyzing the solutions by two different analysts, using different
instruments, using multiple lots of column, in two different
labs and on different days. The percentage RSD obtained un-
der different conditions was below 2%. Table 4 represents the
intermediate and intraday precision.
4.3. System suitability
System suitability is an important parameter to ensure whether
the used method was valid or not. The limit of theoretical
plates and tailing factor was ﬁxed as not less than 6000 and
not more than 2, respectively. All the chromatograms theoret-
ical plates were above 6000 and the tailing factor was less than
1. RSD results from six replicates showed adherence to the lim-
its. The above results indicated that the developed method is
valid and can be used for routine lab analysis.5. Conclusion
The simple, sensitive and inexpensive isocratic RP-HPLC
method was developed to determine the percentage drug
release of CC tablets. The dissolution study showed that CC
has good stability and the percentage drug released was satis-
factory for all the evaluated batches from the formulation. The
validation results show that the method is speciﬁc, accurate,
linear, precise, rugged and robust. The run time is relatively
short (5.0 min) which enables rapid quantiﬁcation of manysamples in routine analysis. Therefore this method is proposed
for the quality control studies of CC modiﬁed and conven-
tional pharmaceutical dosage forms contributing to assure
the therapeutic efﬁcacy of the drug.
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